Brief: Healius Expects FY 2026 Group Underlying EBIT Of A$30 Million-A$35 Million
13/05/2026 06:42
May 13 (Reuters) - Healius Ltd HLS.AX: FY26 TRADING UPDATE AND STRATEGIC REVIEW OF ASSETS EXPECTS FY 2026 GROUP UNDERLYING EBITDA OF A$259 MILLION-A$264 MILLION EXPECTS FY 2026 GROUP UNDERLYING EBIT OF A$30 MILLION-A$35 MILLION ENGAGES UBS TO EXPLORE SALE OF AGILEX BIOLABS INADEQUATE FUNDING HAS RESULTED IN DIFFICULT DECISIONS TO CUT STAFF, OTHERS Further company coverage: HLS.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Healius
See all newsAustralia's Healius rises on sale of unit Agilex; Jefferies lifts PT
Brief: Healius To Sell Agilex Biolabs To Novotech
Australia's Healius rises on sale of unit Agilex Biolabs to Novotech Health
Brief: Healius Requests Trading Halt
Brief: Healius Expects To Achieve T27 Target Of Mid-To-High Single-Digit EBIT Margins By Dec 2028